Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer
Open Access
- 10 October 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (9) , 1195-1201
- https://doi.org/10.1038/sj.bjc.6603348
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized TrialsJournal of Clinical Oncology, 2005
- ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of colon cancerAnnals of Oncology, 2005
- Probabilistic sensitivity analysis for NICE technology assessment: not an optional extraHealth Economics, 2005
- Proteomic analysis for the early detection and rational treatment of cancer—realistic hope?Annals of Oncology, 2005
- American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon CancerJournal of Clinical Oncology, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancerBMJ, 2004
- Management of Colorectal Cancer in Elderly PatientsDrugs & Aging, 2004
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998
- Markov Models in Medical Decision MakingMedical Decision Making, 1993